StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)
August 7, 2023 4:56 PM
Oppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)The analyst comments "SAGE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
BofA Securities Downgrades Sage Therapeutics (SAGE) to Neutral
August 7, 2023 12:56 PM
Sage tumbles to record low on clinical depression pill setback
August 7, 2023 12:44 PM
Stifel Downgrades Sage Therapeutics (SAGE) to Hold, 'we think Biogen is unlikely to buy Sage outright '
August 7, 2023 10:11 AM
Form S-8 Sage Therapeutics, Inc.
August 7, 2023 7:49 AM
Wedbush Downgrades Sage Therapeutics (SAGE) to Neutral
August 7, 2023 7:23 AM
Form 10-Q Sage Therapeutics, Inc. For: Jun 30
August 7, 2023 7:21 AM
SAGE Therapeutics (SAGE) sinks nearly 50% as trading resumes following CRL
August 7, 2023 7:12 AM
Sage, Biogen receive setback despite FDA approval of postpartum depression drug. This is why
August 7, 2023 7:04 AM
SAGE Therapeutics (SAGE) to resume trading at 7:10AM ET
August 7, 2023 6:47 AM
Form 8-K Sage Therapeutics, Inc. For: Aug 07
August 7, 2023 6:46 AM
SAGE Therapeutics (SAGE) Misses Q2 EPS by 13c
August 7, 2023 6:44 AM
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
August 7, 2023 6:30 AM
SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD
August 7, 2023 6:24 AM
RBC Capital Downgrades Sage Therapeutics (SAGE) to Sector Perform
August 7, 2023 3:10 AM
Oppenheimer Downgrades Sage Therapeutics (SAGE) to Perform
August 7, 2023 2:22 AM
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
August 4, 2023 10:45 PM
